← All trials
NCT05950464
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 27, 2024
- Primary completion
- Apr 30, 2026
- Completion date
- Apr 30, 2026
- First posted
- Jul 18, 2023
- Last posted
- Dec 27, 2023
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- NRG OncologyCollaborator
- NRG OncologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.